Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $129.4 million.

  • Compass Therapeutics' Cash from Financing Activities rose 646815000.0% to $129.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $128.5 million, marking a year-over-year increase of 64361.47%. This contributed to the annual value of $17.3 million for FY2024, which is 49073.25% up from last year.
  • Per Compass Therapeutics' latest filing, its Cash from Financing Activities stood at $129.4 million for Q3 2025, which was up 646815000.0% from -$815000.0 recorded in Q1 2025.
  • Over the past 5 years, Compass Therapeutics' Cash from Financing Activities peaked at $129.4 million during Q3 2025, and registered a low of -$815000.0 during Q1 2025.
  • Moreover, its 3-year median value for Cash from Financing Activities was $11000.0 (2023), whereas its average is $14.9 million.
  • Per our database at Business Quant, Compass Therapeutics' Cash from Financing Activities crashed by 10952.38% in 2024 and then surged by 646815000.0% in 2025.
  • Over the past 3 years, Compass Therapeutics' Cash from Financing Activities (Quarter) stood at -$158000.0 in 2023, then surged by 40.51% to -$94000.0 in 2024, then surged by 137718.09% to $129.4 million in 2025.
  • Its Cash from Financing Activities was $129.4 million in Q3 2025, compared to -$815000.0 in Q1 2025 and -$94000.0 in Q4 2024.